Adheris Health Limited
AHE.ASXHealth Care
E-healthcare software developer
Market Data
$0.020
-0.0%$12.8M
-100000.0x
$-0.100
0.00%
-0.6%
Latest Earnings
FY26 Half Year Results
27 February 2026
Adheris Health reported a challenging 1H FY26 with revenue falling 49% to $23.3M and gross profit declining 58.5% to $10.6M, driven by lower US vaccination rates and reduced pharma client budgets. Despite the revenue collapse, EBITDA more than doubled to $10.7M (up 107.5%) and NPAT surged 245.8% to $7.3M, likely reflecting cost-out benefits and the divestiture of the loss-making ANZ business. The company enters 2H FY26 with a refreshed leadership team, a new technology platform, no debt, and a pro-forma cash position of $14.2M, focused on rebuilding revenue through digital and specialty therapeutic expansion. Key points: EBITDA more than doubled to $10.7M (up 107.5%) and NPAT surged 245.8% to $7.3M despite severe revenue decline, reflecting significant cost reduction benefits.; Accelerated cost-out program targeting >30% reduction in operating expenses between FY25 and FY27 is underway and already delivering results.; Pro-forma cash of $14.2M (post Holdback receipt) with zero debt, providing a solid balance sheet foundation for the turnaround.
Recent Announcements
FY26 Half Year Results
Adheris Health reported a challenging 1H FY26 with revenue falling 49% to $23.3M and gross profit declining 58.5% to $10.6M, driven by lower US vaccination rates and reduced pharma client budgets. Despite the revenue collapse, EBITDA more than doubled to $10.7M (up 107.5%) and NPAT surged 245.8% to $7.3M, likely reflecting cost-out benefits and the divestiture of the loss-making ANZ business. The company enters 2H FY26 with a refreshed leadership team, a new technology platform, no debt, and a pro-forma cash position of $14.2M, focused on rebuilding revenue through digital and specialty therapeutic expansion. Key points: EBITDA more than doubled to $10.7M (up 107.5%) and NPAT surged 245.8% to $7.3M despite severe revenue decline, reflecting significant cost reduction benefits.; Accelerated cost-out program targeting >30% reduction in operating expenses between FY25 and FY27 is underway and already delivering results.; Pro-forma cash of $14.2M (post Holdback receipt) with zero debt, providing a solid balance sheet foundation for the turnaround.
Appendix 4D & FY26 Half Year Report
Adheris Health Limited (formerly MedAdvisor Limited) reported HY26 profit of $7.35M, up 423.9% on the prior period, however this result is heavily distorted by a $17.5M one-off gain from the disposal of its ANZ business to Jonas Software in July 2025. Stripping out that gain, the underlying business recorded an operating loss of approximately $10.1M, with continuing operations revenue falling 49% to $23.3M as the company is now a much smaller, US-focused entity. The auditors have flagged a going concern uncertainty given the underlying operating losses and cash outflows. Key points: Statutory NPAT of $7.35M, up 423.9% on pcp of $1.40M; Net tangible assets per share improved significantly to 1.42 cents from -1.96 cents in the prior period; Gross margin of 45.6% on continuing operations revenue of $23.35M
Get real-time alerts for AHE
Receive AI-powered earnings summaries and instant notifications when Adheris Health Limited releases results.
Register Free